[Glurenorm in the treatment of patients with non-insulin-dependent diabetes mellitus with diseases of the liver and bile ducts].

Abstract

Glurenorm, a IInd generation sulfanylurea preparation, was used for a year as a sugar-reducing drug in 20 patients with non-insulin-dependent diabetes mellitus and concomitant diseases of the liver (cirrhosis, chronic hepatitis, n = 5) and biliferous duct (cholelithiasis, a state following cholecystectomy, chronic cholecystitis, n = 15). A year follow-up has not shown deterioration of liver function as indicated by results of liver tests (AST, ALT, acid phosphatase, gamma-glutamyltranspeptidase, bilirubin, cholesterol, triglycerides). The hypoglycemic effect of the drug proved to be inferior to that of sulfanylurea derivatives, but the absence of side effects permit higher doses of glurenorm (up to 4-6 tablets daily) as against other oral sugar-reducing drugs.

• Authors: M I Balabolkin, L V Nedosugova
• Journal: Problemy endokrinologii (Probl Endokrinol (Mosk)) 1993 Jul-Aug Vol. 39 Issue 4 Pg. 16-8 ISSN: 0375-9660 [Print] Russia (Federation)
• Vernacular Title: Primenenie gliurenorma v lechenii bol'nykh insulinnezavisimym sakharnym diabetom s zabolevaniiami pecheni i zhelchevyvodiashchikh puteĭ.
• PMID: 8415521 (Publication Type: English Abstract, Journal Article)

Chemical References

• Hypoglycemic Agents
• Sulfonylurea Compounds
• gliquidone

Topics

• Adult
• Aged
• Bile Duct Diseases (complications)
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Female
• Follow-Up Studies
• Humans
• Hypoglycemic Agents (therapeutic use)
• Liver Diseases (complications)
• Male
• Middle Aged
• Sulfonylurea Compounds (adverse effects, therapeutic use)